Bright Minds Biosciences Inc. Share Price & Technical Analysis
DRUG · $74.67 (-3.61%)
Healthcare / Biotechnology
$74.67
-3.61%
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-4% return in May, 0% avg return in past 3 year May month.
10% return in 2026, 1281% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | 9% | -10% | 18% | -4% | – | – | – | – | – | – | – | 10% |
| 25 | -5% | 14% | -2% | -15% | -16% | 0% | 33% | 17% | 55% | -10% | 27% | 12% | 109% |
| 24 | 47% | -18% | -37% | -17% | 20% | -8% | 20% | -8% | 9% | 3800% | -6% | -19% | 3782% |
| 23 | -8% | -19% | -24% | 41% | -3% | -10% | 50% | -48% | -27% | -7% | 0% | 8% | -47% |
| 22 | -23% | -16% | -28% | -36% | 20% | -27% | 22% | 100% | -30% | -20% | 8% | -31% | -64% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$829.32M
P/E ratio
—
52W high
$123.8
52W low
$23.18
Volume
1,47,706
Beta
-0.19
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Bright Minds Biosciences Inc. share price today?
- Bright Minds Biosciences Inc. (DRUG) last traded around $74.67 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does DRUG have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for DRUG. Download the app for real-time alerts.
- How can I analyze Bright Minds Biosciences Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.